๐ฌ Rapid Detection of Respiratory Diseases โ Highlight from a HighโImpact Study
Tuberculosis remains a major global public health threat, and conventional detection methods have inherent limitations.
This study introduces the CRAFT platform (CRISPRโDriven Aptamer Fluorescence Testing) โ combining aptamer screening, MIRA isothermal amplification, and CRISPRโCas12a detection for direct, ultrasensitive detection of viable Mycobacterium tuberculosis in plasma.
How it works:
๐งฌ Magneticโbead SELEX screened a highโaffinity aptamer (Ap3) targeting the ESAT6/CFP10 fusion protein
๐ An aptamerโblocker probe releases ssDNA blocker strands upon target binding
โก Released strands initiate MIRA amplification, followed by Cas12a detection
๐ Cascade amplification: protein binding โ signal release โ nucleic acid amplification โ fluorescence readout
Performance:
โฑ๏ธ Sampleโtoโresult in 120 minutes
๐ฏ Limit of detection: 0.1 ag/mL
โ
Clinical validation: 97.1% sensitivity, 98.0% specificity
๐ฌ Discriminates viable from dead bacteria โ supporting early treatment evaluation
Powered by MIRA technology from AMPโFUTURE BIOTECH โ enabling ultrasensitive, fieldโready molecular diagnostics for tuberculosis and beyond.
|
Tuberculosis remains a major global public health threat, and conventional detection methods have inherent limitations.
This study introduces the CRAFT platform (CRISPRโDriven Aptamer Fluorescence Testing) โ combining aptamer screening, MIRA isothermal amplification, and CRISPRโCas12a detection for direct, ultrasensitive detection of viable Mycobacterium tuberculosis in plasma.
How it works:
๐งฌ Magneticโbead SELEX screened a highโaffinity aptamer (Ap3) targeting the ESAT6/CFP10 fusion protein
๐ An aptamerโblocker probe releases ssDNA blocker strands upon target binding
โก Released strands initiate MIRA amplification, followed by Cas12a detection
๐ Cascade amplification: protein binding โ signal release โ nucleic acid amplification โ fluorescence readout
Performance:
โฑ๏ธ Sampleโtoโresult in 120 minutes
๐ฏ Limit of detection: 0.1 ag/mL
โ Clinical validation: 97.1% sensitivity, 98.0% specificity
๐ฌ Discriminates viable from dead bacteria โ supporting early treatment evaluation
Powered by MIRA technology from AMPโFUTURE BIOTECH โ enabling ultrasensitive, fieldโready molecular diagnostics for tuberculosis and beyond.